BIOCELL Breast Implant Litigation: MDL 2921 Status

The BIOCELL litigation is a group of federal product liability cases about Allergan’s textured breast implants and tissue expanders and the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The cases are consolidated as MDL 2921 in the District of New Jersey before Judge Brian R. Martinotti. The Judicial Panel on Multidistrict Litigation counted 1,370 actions pending as of October 1, 2026, out of 1,585 filed since 2019. On August 28, 2026, the court stated that the matter “has been resolved in principle,” vacated the November 2, 2026 trial date and stayed all cases pending execution of a final agreement. No agreement, amount or approval motion appears in the docket entries reviewed.

What the product and the recall are

BIOCELL is Allergan’s name for a textured surface applied to breast implants and to tissue expanders used before reconstruction. On July 24, 2019, the FDA announced that it had asked Allergan to recall specific textured models because of the risk of BIA-ALCL, and that Allergan had notified the agency it would carry out a worldwide recall (FDA announcement). The models named were Natrelle saline-filled, silicone-filled, Inspira silicone-filled and 410 implants, with the Natrelle 133 Plus and 133 tissue expanders with suture tabs.

The FDA classified the recall as Class I. The agency’s enforcement database returns 12 records for Allergan BIOCELL products, all initiated on July 24, 2019, all Class I and all listed as ongoing (FDA enforcement records).

The FDA describes BIA-ALCL as a non-Hodgkin lymphoma, not breast cancer. It is usually found in scar tissue or fluid around an implant, and symptoms include persistent swelling, a mass or pain. The agency states that risk is higher for textured implants than for smooth implants, and does not recommend routine removal in patients without symptoms (FDA questions and answers).

What is established vs. what is alleged

Established by the court record

• The consolidation. The Panel’s transfer order of December 18, 2019 centralized four actions from four districts, noted 25 related actions, and assigned the proceeding to Judge Martinotti, citing Allergan USA’s headquarters in New Jersey (transfer order).
• The case count. The Panel’s October 1, 2026 report lists 1,370 actions pending and 1,585 total for MDL 2921 (JPML report).
• The bellwether schedule. Case Management Order No. 37, entered October 14, 2025, required each side to select three cases by June 23, 2026, from which two would be tried. The first trial was set for June 15, 2026, moved to October 19, 2026, and adjourned on February 25, 2026 to November 2, 2026 (July 13, 2026 opinion).
• The venue ruling. In a July 13, 2026 opinion and order, the court held that the six bellwether plaintiffs and the defendants had consented to its jurisdiction and venue in New Jersey for trial. It denied four motions to amend short-form complaints and selected the Henson case first, the Rabin case second (opinion).
• The stay. On August 28, 2026, the court entered a text order stating that the matter “has been resolved in principle,” vacating “all pending deadlines, including the upcoming pretrial deadlines and November 2, 2026 trial date,” and staying all cases “pending execution of a final agreement,” with a status update due within 60 days (MDL docket).

Alleged in the complaints

The transfer order summarizes the claims: that Allergan’s BIOCELL implants and expanders significantly increase the risk of BIA-ALCL, and that Allergan failed to warn the FDA, patients and health care providers. The common questions identified were whether the products can cause BIA-ALCL, whether the defendants knew or should have known of the risk, whether their warnings were adequate, and whether the design, testing and manufacture were adequate (transfer order). Those are allegations. The rulings above concern procedure, venue and scheduling, not causation.

Where the claims stand procedurally

An MDL is not a class action and not a trial. It consolidates pretrial proceedings in one court while each plaintiff keeps an individual case; MDL versus class action explains the difference. MDL 2921 remains on the Panel’s pending list. The 1,370 figure counts actions not yet closed or remanded, not how many claims are being pursued or how many have merit.

The August 28, 2026 order changed the posture of every case: deadlines were vacated, cases were stayed, and the trial set for November 2, 2026 will not go forward on that date. The order states no terms, sets no approval hearing, and directs a status report within 60 days. For current status, check the MDL docket; this article reflects the record as of October 18, 2026.

The FDA’s own case numbers

The FDA’s device report table is a running count of BIA-ALCL reports, not an incidence study. In July 2019 the agency reported 573 unique cases and 33 deaths worldwide, 481 of them attributed to Allergan implants, and stated that the risk with Allergan BIOCELL implants was approximately six times the risk with other textured implants (FDA announcement).

The current table, reflecting reports received through June 30, 2024, lists 1,380 unique cases and 64 deaths (FDA device reports). The agency cautions that reporting is passive, with incomplete, duplicated or unverified reports, so the table cannot be used to calculate incidence among people with implants.

Key dates

• July 24, 2019: the FDA requests the recall of specific Allergan BIOCELL implants and tissue expanders; Allergan announces a worldwide recall; the action is classified Class I.
• December 18, 2019: the Panel creates MDL 2921 and assigns it to Judge Martinotti in New Jersey.
• June 30, 2024: cutoff for the FDA’s most recent published BIA-ALCL case table (1,380 cases, 64 deaths).
• October 14, 2025: Case Management Order No. 37 sets the bellwether selection process.
• July 13, 2026: the court rules on venue and amendment and selects the first two bellwether cases.
• August 28, 2026: the court reports a resolution in principle, vacates the trial date and stays all cases.
• October 1, 2026: the Panel reports 1,370 actions pending and 1,585 filed.

What this does not establish

Nothing in the record reviewed here finds that a BIOCELL implant caused any person’s BIA-ALCL. No trial or verdict has occurred in MDL 2921. The August 28, 2026 order describes a resolution in principle; it is not a settlement agreement, court approval, or statement of any amount. The recall concerns the risk of a disease, not a finding about any individual. The FDA’s table cannot show how likely any person is to develop BIA-ALCL, because it has no denominator and depends on voluntary reporting.

Frequently asked questions

Is the BIOCELL litigation a class action?

No. It is a multidistrict proceeding in which individual plaintiffs keep separate cases consolidated for pretrial purposes. See MDL versus class action.

Has a court found that BIOCELL implants cause BIA-ALCL?

No court finding appears in the record reviewed here. The FDA has associated textured implants with the disease and requested the Allergan recall; the lawsuits allege causation; the July 2026 ruling decided venue and scheduling.

Has the litigation settled?

The court said on August 28, 2026 that the matter had been “resolved in principle” and stayed the cases pending a final agreement. No agreement, amount or approval motion appears in the docket entries reviewed, so the terms are not established.

Should someone with these implants have them removed?

The FDA states that it is not recommending routine removal in patients who have no symptoms, and that patients with symptoms such as persistent swelling or pain should be evaluated. That is the agency’s guidance, not legal advice; medical questions belong to a treating clinician.

Sources

1. United States Judicial Panel on Multidistrict Litigation: “MDL Statistics Report - Distribution of Pending MDL Dockets by District” (link, accessed 2026-10-18)
2. United States Judicial Panel on Multidistrict Litigation: “Transfer Order, In re Allergan Biocell Textured Breast Implant Products Liability Litigation, MDL No. 2921” (link, accessed 2026-10-18)
3. Free Law Project, RECAP archive of the United States Judicial Panel on Multidistrict Litigation: “Docket, In re Allergan Biocell Textured Breast Implant Products Liability Litigation, MDL No. 2921 (J.P.M.L.)” (link, accessed 2026-10-18)
4. Free Law Project, RECAP archive of the U.S. District Court for the District of New Jersey: “Docket, In re Allergan Biocell Textured Breast Implant Products Liability Litigation, No. 2:19-md-02921 (D.N.J.)” (link, accessed 2026-10-18)
5. U.S. District Court for the District of New Jersey: “Opinion and Order, In re Allergan Biocell Textured Breast Implant Products Liability Litigation, No. 2:19-md-02921, ECF No. 685” (link, accessed 2026-10-18)
6. U.S. Food and Drug Administration: “FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market” (link, accessed 2026-10-18)
7. U.S. Food and Drug Administration: “Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)” (link, accessed 2026-10-18)
8. U.S. Food and Drug Administration: “Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma” (link, accessed 2026-10-18)
9. U.S. Food and Drug Administration: “Device Enforcement Reports for Allergan BIOCELL breast implants and tissue expanders” (link, accessed 2026-10-18)

CollectiveClaim.us publishes general legal information. This article is not legal advice and does not create an attorney–client relationship. Court records and agency actions change; verify current status with the court or agency before relying on it.